PDCD1 and hepatocellular carcinoma: In global phase 3 trials, anti-PD-1 antibody monotherapy administered in the first-line1 and second-line2 settings has failed to improve overall survival (OS) among patients with unresectable hepatocellular carcinoma (uHCC).